OsteoProtect
- Summary
- Treatment of osteoporosis by inhibitors of sphingosine-1-phosphatase (S1P)-lyase.
- Technology Benefits
- Novel approach for treating reduced bone density/stability
Specific inhibitors identified
In vivo data available
- Technology Application
- Pharmacological therapy for osteoporotic fractures.
- Detailed Technology Description
- The inventors showed that S1P inhibited osteoclast function, but most importantly, stimulated osteoblasts to produce new bone. Thus, a sufficient S1P-concentration is fundamental for an osteoanabolic fine-tuning of the skelettal system. Furthermore they showed that high S1P counteracts obesity by reducing adipose tissue mass. According to the invention, in patients suffering from osteoporosis, bone formation may be facilitated (and obesity reduced) by administering inhibitors of the S1P-lyase (the key enzyme degrading S1P). An exemplary S1P-lyase inhibitor tested by the inventors is the compound 4deoxypyridoxin (DOP).
- Type of Cooperation
- Licensing
- Application Date
- 07/03/2019 00:00:00
- Application No.
- WO2019EP55667 20190307
- Classes
-
- international:
A61K31/417; A61K31/4415; A61K31/4439; A61P19/10; A61P3/06; A61P3/08
- cooperative:
A61K31/417 (EP); A61K31/4415 (EP); A61K31/4439 (EP); A61P19/10 (EP); A61P3/06 (EP); A61P3/08 (EP)
- Others
- Patent application
- ID No.
- 4955
- Country/Region
- Germany
For more information, please click Here